Latanoprost/netarsudil mesylate - Aerie Pharmaceuticals

Drug Profile

Latanoprost/netarsudil mesylate - Aerie Pharmaceuticals

Alternative Names: Latanoprost/AR-13324; Netarsudil/latanoprost ophthalmic solution - Aerie Pharmaceuticals; PG324; Roclatan

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aerie Pharmaceuticals
  • Class Antiglaucomas; Prostaglandins
  • Mechanism of Action Norepinephrine plasma membrane transport protein inhibitors; Prostaglandin F2 alpha agonists; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Glaucoma; Ocular hypertension

Most Recent Events

  • 27 Mar 2018 Chemical structure information added
  • 22 Mar 2018 Aerie Pharmaceuticals announces intention to submit MAA to the EMA for Glaucoma and Ocular hypertension in the end of 2019
  • 08 Nov 2017 Aerie Pharmaceuticals plans a regulatory filing in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top